

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-------------------|----------------------------------|-----------------|--------------|
| Applicant: | REIMER | Examiner: | UNKNOWN |
| Serial No.: | 10/551,303 | Group Art Unit: | 1614 |
| Filed: | SEPTEMBER 27, 2005 | Docket No.: | 12695.17USWO |
| Confirmation No.: | 6451 | Customer No.: | 23552 |
| Title: | COMPOSITIONS FOR TREATING ANGINA | | |

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

A copy of any foreign patent document or "Other Document" listed on the Form 1449 is enclosed, in accordance with 37 C.F.R. §1.98(a)(2). Because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. patent publications listed on the enclosed Form 1449 are not provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked


as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: 8/16/2007



Brian R. Dorn
Reg. No. 57,395

23552
PATENT TRADEMARK OFFICE

| | | | | |
|--|--|--|--|-----------------------------------|
| FORM 1449* INFORMATION DISCLOSURE STATEMENT | | | Docket Number: 12695.17USWO | Application Number: 10/551,303 |
| IN AN APPLICATION (Use several sheets if necessary) | | | Applicant: Reimer Filing Date: Nov. 16, 2006 Group Art Unit: 1614 | |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|--------------|------------|---------------|-------|----------|----------------------------|
| EXAMINER INITIAL | DOCUMENT NO. | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | 3,282,778 | 11/1/1966 | Lobel | | | |
| | 6,417,204 B1 | 07/09/2002 | Haque | | | |
| | 6,489,345 | 12/3/2002 | Sethi | | | |
| | 6,548,519 B1 | 04/15/2003 | Haque | | | |
| | 6,586,414 | 7/1/2003 | Haque et al. | | | |
| | 6,605,612 B2 | 08/12/2003 | Haque | | | |
| | 6,667,315 B2 | 12/23/2003 | Haque | | | |
| | 6,677,356 | 1/13/2004 | Sethi et al. | | | |
| | 6,780,997 B2 | 08/24/2004 | Haque | | | |
| | 6,861,439 B2 | 03/01/2005 | Haque et al. | | | |
| | 6,867,215 B2 | 03/15/2005 | Haque | | | |
| | 6,890,943 B2 | 05/10/2005 | Haque | | | |
| | 6,897,228 B2 | 05/24/2005 | Haque | | | |
| | 7,105,673 B2 | 09/12/2006 | Haque | | | |
| | 7,115,625 B2 | 10/03/2006 | Sethi et al. | | | |
| | 7,115,626 B2 | 10/03/2006 | Sethi et al. | | | |
| | 7,125,889 B2 | 10/24/2006 | Sethi et al. | | | |
| | 7,132,430 B2 | 11/07/2006 | Sethi et al. | | | |
| | 7,144,892 B2 | 12/05/2006 | Sethi et al. | | | |
| | 7,148,233 B2 | 12/12/2006 | Sethi et al. | | | |
| | 7,230,009 B2 | 06/12/2007 | Haque et al. | | | |
| | 2004/0186077 | 09/23/2007 | Diakur et al. | | | |
| | 10/215,739 | | Sethi | | | 8-8-2002 |
| | 10/549,505 | | | | | |
| | 10/551,302 | | | | | |
| | 10/584,332 | | | | | |
| | 10/729,276 | | | | | |
| | 10/732,037 | | | | | |
| | 10/881,864 | | Sethi | | | 6-30-2004 |

| | |
|---|-----------------|
| EXAMINER | DATE CONSIDERED |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. | |

| | | | |
|---|--|--------------------------------|-----------------------------------|
| FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary) | | Docket Number: 12695.17USWO | Application Number: 10/551,303 |
| | | Applicant: Reimer | |
| | | Filing Date: Nov. 16, 2006 | Group Art Unit: 1614 |

| | | | | | | |
|--|------------|--|---------|--|--|-----------|
| | 10/974,707 | | | | | |
| | 10/974,718 | | | | | |
| | 11/016,737 | | | | | |
| | 11/177,248 | | | | | |
| | 11/202,272 | | Friesen | | | 8-10-2005 |
| | 11/262,509 | | | | | |
| | 11/288,971 | | | | | |
| | 11/326,201 | | | | | |
| | 11/424,069 | | Friesen | | | 6-14-2006 |
| | 11/564,192 | | | | | |
| | 11/631,726 | | | | | |
| | 11/662,351 | | | | | |
| | 11/663,824 | | | | | |
| | 11/672,140 | | | | | |
| | 11/720,422 | | | | | |
| | 11/739,920 | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NO. | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|----------------|----------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | WO 01/13900 A2 | 3-1-2001 | WIPO | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|--|--|
| | American Heart Association, "Heart Disease and Stroke Statistics—2003 Update," Dallas, TX: American Heart Association; 2002. |
| | Berge et al., "Pharmaceutical Salts." <i>Journal of Pharmaceutical Sciences</i> Vol.66 No.1 (1977), p.1-16. |
| | Dyck et al., "Malonyl CoA Control of Fatty Acid Oxidation in the Ischemic Heart." <i>J. Mol. Cell. Cardiol.</i> , Vol.34 (2002), p. 1099-1109. |
| | Lopaschuk et al., "Glucose Metabolism in the Ischemic Heart." <i>Circulation</i> , Vol.95 (1997), p. 313-315. |
| | Pham et al., "Design and Synthesis of Novel Pyridoxine 5'-Phosphonates as Potential Antiischemic Agents." <i>J. Med. Chem.</i> (2003), 46:3680-3687. |

| | |
|---|-----------------|
| EXAMINER | DATE CONSIDERED |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. | |

| | | | |
|---|--|--------------------------------|-----------------------------------|
| FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary) | | Docket Number: 12695.17USWO | Application Number: 10/551,303 |
| | | Applicant: Reimer | |
| | | Filing Date: Nov. 16, 2006 | Group Art Unit: 1614 |

| | |
|--|--|
| | Rupp et al., "The Use of Partial Fatty Acid Oxidation Inhibitors for Metabolic Therapy of Angina Pectoris and Heart Failure." <i>Herz</i> (2002), Vol. 27 No.7, p.621-636. |
| | Stanley, William C. "Partial Fatty Acid Oxidation Inhibitors for Stable Angina." <i>Expert Opinion Investig. Drugs</i> (2002); 11 (5), p.615-629. |
| | STEDMAN'S MEDICAL DICTIONARY. Baltimore, MD: Waverly Press, Inc., 1961, p.101. |

| | |
|---|-----------------|
| EXAMINER | DATE CONSIDERED |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. | |